Table of Content

1. Key Insights

2. Epstein–Barr Virus: Market Overview at a Glance
2.1. Market Share (%) Distribution of EBV in 2017
2.2. Market Share (%) Distribution of EBV in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Epstein–Barr Virus (EBV)
5.1. Introduction
5.2. Classification
5.3. Signs and Symptoms
5.4. Etiology
5.5. Pathogenesis
5.6. EBV Associated Diseases
5.7. Diagnosis
5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM
6.3. Total Incident Population of EBV+ Cancers and PTLD in 7MM

7. 7MM Epidemiology of EBV
7.1. Assumptions and Rationale
7.2. The United States
7.2.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the US
7.2.2. Total Incident cases of EBV+ Cancers in the US
7.2.3. Total Incident cases of EBV+ PTLD in the US
7.3. Germany
7.3.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Germany
7.3.2. Total Incident cases of EBV+ Cancers in Germany
7.3.3. Total Incident cases of EBV+ PTLD in Germany
7.4. France
7.4.1. Total Diagnosed cases of EBV Infectious Mononucleosis in France
7.4.2. Total Incident cases of EBV+ Cancers in France
7.4.3. Total Incident cases of EBV+ PTLD in France
7.5. Italy
7.5.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Italy
7.5.2. Total Incident cases of EBV+ Cancers in Italy
7.5.3. Total Incident cases of EBV+ PTLD in Italy
7.6. Spain
7.6.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Spain
7.6.2. Total Incident cases of EBV+ Cancers in Spain
7.6.3. Total Incident cases of EBV+ PTLD in Spain
7.7. The United Kingdom
7.7.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the UK
7.7.2. Total Incident cases of EBV+ Cancers in the UK
7.7.3. Total Incident cases of EBV+ PTLD in the UK
7.8. Japan
7.8.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Japan
7.8.2. Total Incident cases of EBV+ Cancers in Japan
7.8.3. Total Incident cases of EBV+ PTLD in Japan

8. Treatment and Management

9. Unmet Needs

10. Emerging Therapies
10.1. Key Cross Competition
10.2. Tabelecleucel: Atara Biotherapeutics
10.2.1. Drug Description
10.2.2. Other development activities
10.2.3. Clinical development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Viralym-M: AlloVir
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. TT10: Tessa Therapeutics
10.4.1. Drug Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. Nanatinostat: Viracta Therapeutics
10.5.1. Drug Description
10.5.2. Other development activities
10.5.3. Clinical Development
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.6. Brentuximab Vedotin: Seagen
10.6.1. Drug Description
10.6.2. Other development activities
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. FLX475: RAPT Therapeutics
10.7.1. Drug Description
10.7.2. Other development Activities
10.7.3. Clinical development
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Other Potential Therapies
10.9. Pembrolizumab: Merck
10.9.1. Drug Description
10.9.2. Clinical Development
10.9.3. Product Profile
10.10. EBViNT: Eutilex
10.10.1. Drug description
10.10.2. Other Development Activities
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile
10.11. ATA188: Atara Biotherapeutics
10.11.1. Drug Description
10.11.2. Clinical Development
10.11.3. Safety and Efficacy
10.11.4. Product Profile
10.12. 2LEBV and 2LXFS: Labolife
10.12.1. Drug Description
10.12.2. Clinical development
10.12.3. Product Profile

11. Epstein–Barr Virus: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of EBV in 7MM

12. Market Outlook: 7MM
12.1. EBV-Vaccine
12.2. EBV+ Cancers/PTLD
12.3. The United States Market Size
12.3.1. The Total Market Size of EBV in the United States
12.3.2. The Market Size of EBV Infectious Mononucleosis in the United States
12.3.3. The Market Size of EBV+ Cancers and PTLD in the United States (1L)
12.3.4. The Market Size of EBV+ Cancers and PTLD in the United States (R/R)
12.4. Germany Market Size
12.4.1. The Total Market Size of EBV in Germany
12.4.2. The Market Size of EBV Infectious Mononucleosis in Germany
12.4.3. The Market Size of EBV+ Cancers and PTLD in Germany (1L)
12.4.4. The Market Size of EBV+ Cancers and PTLD in Germany (R/R)
12.5. France Market Size
12.5.1. The Total Market Size of EBV in France
12.5.2. The Market Size of EBV Infectious Mononucleosis in France
12.5.3. The Market Size of EBV+ Cancers and PTLD in France (1L)
12.5.4. The Market Size of EBV+ Cancers and PTLD in France (R/R)
12.6. Italy Market Size
12.6.1. The Total Market Size of EBV in Italy
12.6.2. The Market Size of EBV Infectious Mononucleosis in Italy
12.6.3. The Market Size of EBV+ Cancers and PTLD in Italy (1L)
12.6.4. The Market Size of EBV+ Cancers and PTLD in Italy (R/R)
12.7. Spain Market Size
12.7.1. The Total Market Size of EBV in Spain
12.7.2. The Market Size of EBV Infectious Mononucleosis in Spain
12.7.3. The Market Size of EBV+ Cancers and PTLD in Spain (1L)
12.7.4. The Market Size of EBV+ Cancers and PTLD in Spain (R/R)
12.8. The UK Market Size
12.8.1. The Total Market Size of EBV in the UK
12.8.2. The Market Size of EBV Infectious Mononucleosis in the UK
12.8.3. The Market Size of EBV+ Cancers and PTLD in the UK (1L)
12.8.4. The Market Size of EBV+ Cancers and PTLD in the UK (R/R)
12.9. Japan Market Size
12.9.1. The Total Market Size of EBV in Japan
12.9.2. The Market Size of EBV Infectious Mononucleosis in Japan
12.9.3. The Market Size of EBV+ Cancers and PTLD in Japan (1L)
12.9.4. The Market Size of EBV+ Cancers and PTLD in Japan (R/R)

13. Market Drivers

14. Market Barriers

15. Market Access

16. SWOT Analysis

17. Case Studies
17.1. How I treat T-cell chronic active Epstein-Barr virus disease
17.2. Chronic Active Epstein-Barr virus Infection Mimicking Diabetic Ketoacidosis
17.3. Epstein-Barr virus Infection in an Elderly Non-immunocompromised Adult Successfully Treated with Rituximab

18. KOL Views
19. Bibliography
20. Appendix
20.1. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight



List of Figures


Figure 1: Classification of the EBV virus
Figure 2: Symptoms of Infectious Mononucleosis
Figure 3: Risk factors associated with EBV infection
Figure 4: Cell transformation and cell proliferation of tumor cell lines in EBV-cancers
Figure 5: The Epstein–Barr virus genome
Figure 6: Putative in vivo interactions between Epstein–Barr virus and host cells
Figure 7: Activities of Selected EBV Proteins
Figure 8: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017–2030)
Figure 9: Total Incident Population of EBV+ Cancers and PTLD in 7MM (2017–2030)
Figure 10: Global burden of EBV-attributable malignancies- 2017
Figure 11: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)
Figure 12: Total Incident Cases of EBV+ Cancer in the US (2017-2030)
Figure 13: Total Incident Cases of EBV+ PTLD in the US (2017-2030)
Figure 14: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)
Figure 15: Total Incident Cases of EBV+ Cancer in Germany (2017-2030)
Figure 16: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)
Figure 17: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)
Figure 18: Total Incident Cases of EBV+ Cancer in France (2017-2030)
Figure 19: Total Incident Cases of EBV+ PTLD in France (2017-2030)
Figure 20: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)
Figure 21: Total Incident Cases of EBV+ Cancer in Italy (2017-2030)
Figure 22: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)
Figure 23: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)
Figure 24: Total Incident Cases of EBV+ Cancer in Spain (2017-2030)
Figure 25: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)
Figure 26: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)
Figure 27: Total Incident Cases of EBV+ cancer in the UK (2017-2030)
Figure 28: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)
Figure 29: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)
Figure 30: Total Incident Cases of EBV+ Cancer in Japan (2017-2030)
Figure 31: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)
Figure 32: Treatment of IM
Figure 33: Algorithm for management and treatment of PTLD
Figure 34: Treatment algorithm of PTLD
Figure 35: Prevention of EBV infection
Figure 36: Unmet Needs
Figure 37: Market Size of EBV in USD Million (2017–2030)
Figure 38: Market Size of EBV in the US, USD Millions (2017–2030)
Figure 39: Market Size of EBV Infectious Mononucleosis in the US, USD Millions (2017–2030)
Figure 40: Market Size of EBV+ Cancers and PTLD in the US (1L), USD Millions (2017–2030)
Figure 41: Market Size of EBV+ Cancers and PTLD R/R in the US, USD Millions (2017–2030)
Figure 42: Market Size of EBV in Germany, USD Millions (2017–2030)
Figure 43: Market Size of EBV Infectious Mononucleosis in Germany, USD Millions (2017–2030)
Figure 44: Market Size of EBV+ Cancers and PTLD in Germany (1L), USD Millions (2017–2030)
Figure 45: Market Size of EBV+ Cancers and PTLD R/R in Germany, USD Millions (2017–2030)
Figure 46: Market Size of EBV in France, USD Millions (2017–2030)
Figure 47: Market Size of EBV Infectious Mononucleosis in France, USD Millions (2017–2030)
Figure 48: Market Size of EBV+ Cancers and PTLD in France (1L), USD Millions (2017–2030)
Figure 49: Market Size of EBV+ Cancers and PTLD R/R in France, USD Millions (2017–2030)
Figure 50: Market Size of EBV in Italy, USD Millions (2017–2030)
Figure 51: Market Size of EBV Infectious Mononucleosis in Italy, USD Millions (2017–2030)
Figure 52: Market Size of EBV+ Cancers and PTLD in Italy (1L), USD Millions (2017–2030)
Figure 53: Market Size of EBV+ Cancers and PTLD R/R in Italy, USD Millions (2017–2030)
Figure 54: Market Size of EBV in Spain, USD Millions (2017–2030)
Figure 55: Market Size of EBV Infectious Mononucleosis in Spain, USD Millions (2017–2030)
Figure 56: Market Size of EBV+ Cancers and PTLD in Spain (1L), USD Millions (2017–2030)
Figure 57: Market Size of EBV+ Cancers and PTLD R/R in Spain, USD Millions (2017–2030)
Figure 58: Market Size of EBV in the UK, USD Millions (2017–2030)
Figure 59: Market Size of EBV Infectious Mononucleosis in the UK, USD Millions (2017–2030)
Figure 60: Market Size of EBV+ Cancers and PTLD in the UK (1L), USD Millions (2017–2030)
Figure 61: Market Size of EBV+ Cancers and PTLD R/R in the UK, USD Millions (2017–2030)
Figure 62: Market Size of EBV in Japan, USD Millions (2017–2030)
Figure 63: Market Size of EBV Infectious Mononucleosis in Japan, USD Millions (2017–2030)
Figure 64: Market Size of EBV+ Cancers and PTLD in Japan (1L), USD Millions (2017–2030)
Figure 65: Market Size of EBV+ Cancers and PTLD R/R in Japan, USD Millions (2017–2030)
Figure 66: Market Barriers
Figure 67: Market Barriers


List of Tables


Table 1: Prevalence of signs, symptoms, and laboratory abnormalities in infectious mononucleosis
Table 2: Complications reported in ?1% of cases of infectious mononucleosis
Table 3: Biological activities of Epstein Barr virus latency stage gene products
Table 4:Expression of EBV latent genes associated with latency programs
Table 5: EBV associated diseases
Table6: Epstein-Barr virus-positive versus Epstein-Barr virus-negative PTLD
Table 7: Early versus late-onset PTLD in adults
Table 8: Serological profiles in EBV reactivation and EBV-associated diseases
Table 9: Interpretation of Epstein–Barr virus serological profiles in immunocompetent patients
Table 10: Interpretation of IgG avidity test with immunoblotting
Table 11: Advantages and Disadvantages of various EBV diagnostic methods
Table 12: Differential Diagnosis
Table 13: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017–2030)
Table 14: Total Incident Population of EBV+ Cancers and PTLD in 7MM
Table 15: Major Sources used to derive cancer and transplantation cases
Table 16: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)
Table 17: Total Incident Cases of EBV+ Cancers in the US (2017-2030)
Table 18: Total Incident Cases of EBV+ PTLD in the US (2017-2030)
Table 19: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)
Table 20: Total Incident Cases of EBV+ Cancers in Germany (2017-2030)
Table 21: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)
Table 22: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)
Table 23: Total Incident Cases of EBV+ Cancers in France (2017-2030)
Table 24: Total Incident Cases of EBV+ PTLD in France (2017-2030)
Table 25: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)
Table 26: Total Incident Cases of EBV+ Cancers in Italy (2017-2030)
Table 27: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)
Table 28: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)
Table 29: Total Incident Cases of EBV+ Cancers in Spain (2017-2030)
Table 30: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)
Table 31: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)
Table 32: Total Incident Cases of EBV+ Cancers in the UK (2017-2030)
Table 33: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)
Table 34: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)
Table 35: Total Incident Cases of EBV+ Cancers in Japan (2017-2030)
Table 36: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)
Table 37: Available therapies for EBV diseases
Table 38:Treatment Recommendation for PTLD
Table 39: Tabelecleucel, Clinical Trial Description, 2020
Table 40: Viralym-M, Clinical Trial Description, 2020
Table 41: TT10, Clinical Trial Description, 2020
Table 42: VRx-3996, Clinical Trial Description, 2020
Table 43: Brentuximab Vedotin, Clinical Trial Description, 2020
Table 44: FLX475, Clinical Trial Description, 2020
Table 45: Bevacizumab and Pembrolizumab, Clinical Trial Description, 2020
Table 46: EBViNT, Clinical Trial Description, 2020
Table 47: ATA188, Clinical Trial Description, 2020
Table 48: 2LEBV and 2LXFS, Clinical Trial Description, 2020
Table 49: Market Size of EBV in 7MM in USD Million (2017–2030)
Table 50: Market Size of EBV in the US in USD Million (2017–2030)
Table 51: Market Size of EBV Infectious Mononucleosis in the US in USD Million (2017–2030)
Table 52: The US Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 53: The US Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 54: Market Size of EBV in Germany in USD Million (2017–2030)
Table 55: Market Size of EBV Infectious Mononucleosis in Germany in USD Million (2017–2030)
Table 56: Germany Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 57: Germany Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 58: Market Size of EBV in France in USD Million (2017–2030)
Table 59: Market Size of EBV Infectious Mononucleosis in France in USD Million (2017–2030)
Table 60: France Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 61: France Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 62: Market Size of EBV in Italy in USD Million (2017–2030)
Table 63: Market Size of EBV Infectious Mononucleosis in Italy in USD Million (2017–2030)
Table 64: Italy Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 65: Italy Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 66: Market Size of EBV in Spain in USD Million (2017–2030)
Table 67: Market Size of EBV Infectious Mononucleosis in Spain in USD Million (2017–2030)
Table 68: Spain Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 69: Spain Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 70: Market Size of EBV in the UK in USD Million (2017–2030)
Table 71: Market Size of EBV Infectious Mononucleosis in the UK in USD Million (2017–2030)
Table 72: The UK Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 73: The UK Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)
Table 74: Market Size of EBV in Japan in USD Million (2017–2030)
Table 75: Market Size of EBV Infectious Mononucleosis in Japan in USD Million (2017–2030)
Table 76: Japan Market Size of EBV+ Cancers and PTLD (1L), in USD Million (2017–2030)
Table 77:Japan Market Size of EBV+ Cancers and PTLD (R/R), in USD Million (2017–2030)